Aquestive Therapeutics, Inc. Interest and Other Income
Aquestive Therapeutics, Inc. (AQST) reported Interest and Other Income of $99.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-31.
Discontinued › Income Statement › Other Income
us-gaap:InterestAndOtherIncome · last filed 2023-03-31
- Aquestive Therapeutics, Inc. interest and other income for the quarter ending 2020-03-31 was $102.00K, a 62.77% decline year-over-year.
- Aquestive Therapeutics, Inc. interest and other income for the quarter ending 2019-12-31 was $71.00K, a 77.39% decline year-over-year.
- Aquestive Therapeutics, Inc. interest and other income for the quarter ending 2019-09-30 was $138.00K, a 36.11% decline year-over-year.
- Aquestive Therapeutics, Inc. interest and other income for the quarter ending 2019-06-30 was $153.00K.
- Aquestive Therapeutics, Inc. interest and other income for fiscal 2022 was $99.00K, a 76.60% decline from fiscal 2021.
- Aquestive Therapeutics, Inc. interest and other income for fiscal 2021 was $423.00K, a 220.45% increase from fiscal 2020.
- Aquestive Therapeutics, Inc. interest and other income for fiscal 2020 was $132.00K, a 79.25% decline from fiscal 2019.
- Aquestive Therapeutics, Inc. interest and other income for fiscal 2019 was $636.00K, a 15.22% increase from fiscal 2018.
| Period end | Interest and Other Income 3 month | Interest and Other Income 6 month | Interest and Other Income 9 month | Interest and Other Income 12 month |
|---|---|---|---|---|
| 2022-12-31 | $99.00K 10-K · filed 2023-03-31 | |||
| 2021-12-31 | $423.00K 10-K · filed 2023-03-31 | |||
| 2020-12-31 | $132.00K 10-K · filed 2022-03-08 | |||
| 2020-03-31 | $102.00K 10-Q · filed 2020-05-05 | $173.00K derived: sum of 2 quarters · filed 2020-05-05 | $311.00K derived: sum of 3 quarters · filed 2020-05-05 | $464.00K derived: sum of 4 quarters · filed 2020-05-05 |
| 2019-12-31 | $71.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $209.00K derived: sum of 2 quarters · filed 2020-03-11 | $362.00K derived: sum of 3 quarters · filed 2020-03-11 | $636.00K 10-K · filed 2020-03-11 |
| 2019-09-30 | $138.00K 10-Q · filed 2019-11-05 | $291.00K derived: sum of 2 quarters · filed 2019-11-05 | $565.00K 10-Q · filed 2019-11-05 | $879.00K derived: sum of 4 quarters · filed 2020-05-05 |
| 2019-06-30 | $153.00K 10-Q · filed 2019-08-06 | $427.00K 10-Q · filed 2019-08-06 | $741.00K derived: sum of 3 quarters · filed 2020-05-05 | $957.00K derived: sum of 4 quarters · filed 2020-05-05 |
| 2019-03-31 | $274.00K 10-Q · filed 2020-05-05 | $588.00K derived: sum of 2 quarters · filed 2020-05-05 | $804.00K derived: sum of 3 quarters · filed 2020-05-05 | $804.00K derived: sum of 4 quarters · filed 2020-05-05 |
| 2018-12-31 | $314.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $530.00K derived: sum of 2 quarters · filed 2020-03-11 | $530.00K derived: sum of 3 quarters · filed 2020-03-11 | $552.00K 10-K · filed 2020-03-11 |
| 2018-09-30 | $216.00K 10-Q · filed 2019-11-05 | $216.00K derived: sum of 2 quarters · filed 2019-11-05 | $238.00K 10-Q · filed 2019-11-05 | $240.00K derived: sum of 4 quarters · filed 2019-11-05 |
| 2018-06-30 | $0.00 10-Q · filed 2019-08-06 | $22.00K 10-Q · filed 2019-08-06 | $24.00K derived: sum of 3 quarters · filed 2019-08-06 | $24.00K derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-03-31 | $24.00K 10-Q · filed 2019-05-08 | $24.00K derived: sum of 2 quarters · filed 2019-05-08 | $24.00K derived: sum of 3 quarters · filed 2019-05-08 | |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $0.00 derived: sum of 2 quarters · filed 2019-03-14 | $0.00 10-K · filed 2019-03-14 | |
| 2017-09-30 | $0.00 10-Q · filed 2018-11-06 | $0.00 10-Q · filed 2018-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |